Back to Agenda
[Session 1] Announcement of ICH S7B
Session Chair(s)
Satoshi Tsunoda
Specialist, Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
![Takashi Yoshinaga](/_Images/member/Generic_Image_Missing-Profile.jpg)
Takashi Yoshinaga
Executive Director, Advanced Biosignal Safety Assessment
Eisai Co., Ltd., Japan
Speaker(s)
ICH S7B Q&A Points to Consider (Step 2) In Vitro Best Practice
Gary Gintant, PhD
AbbVie Inc., United States
Research Fellow
ICH S7B Q&A Point to consider, In vivo best practice
Katsuyoshi Chiba, PhD
Daiichi Sankyo Co., Ltd., Japan
Senior Director and Head, Group III, Medicinal Safety Research Laboratories, R&D
![Zhihua Li, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
ICH S7B Q&A: Points to consider for S7B Integrated Risk Assessment
Zhihua Li, PhD
Food and Drug Administration, United States
Biologist, Div. of Applied Regulatory Science, Office of Clinical Pharmacology,
Have an account?